Gene,Therapeutic,Gene Acession (NC_063383),Protein,Start (nt),Stop (nt),Resistance Mutations,Residues of interest,References,Virus-Specific Validation
F13L,Tecovirimat,OPG057,Palmytilated EEV membrane protein ,39077,40195,"H238Q, Y258C, N267D, N267del, D283G, A288P, A290V, D294V, A295E, L297ins, I372N, T289A, P243S, T220A/I, T245I, A265D, T289A","238, 258, 267, 283, 288, 290, 294, 295, 297, 372, 289, 243, 220, 245, 265, 289","Mertes, H., Rezende, A. M., Brosius, I., Naesens, R., Michiels, J., deBlock, T., ... & Vercauteren, K. (2023). Tecovirimat resistance in an immunocompromised patient with mpox and prolonged viral shedding. Annals of Internal Medicine, 176(8), 1141-1143. Smith, T. G., Gigante, C. M., Wynn, N. T., Matheny, A., Davidson, W., Yang, Y., ... & Hutson, C. L. (2023). Tecovirimat resistance in mpox patients, United States, 2022-2023. Emerging Infectious Diseases, 29(12), 2426. Garrigues, J. M., Hemarajata, P., Karan, A., Shah, N. K., Alarc, J., Marutani, A. N., ... & Green, N. M. (2023). Identification of tecovirimat resistance-associated mutations in human monkeypox virus-Los Angeles County. Antimicrobial Agents and Chemotherapy, 67(7), e00568-23.",MPOX
E9L,Brincidofovir/Cidofovir,OPG071,DNA polymerase (2),51418,54438,"L108F, A314T, A684V","108, 314, 684","Kannan, S. R., Sachdev, S., Reddy, A. S., Kandasamy, S. L., Byrareddy, S. N., Lorson, C. L., & Singh, K. (2022). Mutations in the monkeypox virus replication complex: potential contributing factors to the 2022 outbreak. Journal of Autoimmunity, 133, 102928.",MPOX
F4L,Hydroxyurea,OPG048,Ribonucleotide reductase small subunit,31205,32164,-,-,"Slabaugh, M. B., & Mathews, C. K. (1986). Hydroxyurea-resistant vaccinia virus: overproduction of ribonucleotide reductase. Journal of virology, 60(2), 506-514.",VACV
I4L,Hydroxyurea,OPG080,Ribonucleoside-diphosphate reductase (2),59703,62018,-,-,"Slabaugh, M. B., & Mathews, C. K. (1986). Hydroxyurea-resistant vaccinia virus: overproduction of ribonucleotide reductase. Journal of virology, 60(2), 506-514.",VACV
A50R,Mitoxantrone,OPG180,DNA ligase (2),152692,154371,-,-,"Deng, L., Dai, P., Ciro, A., Smee, D. F., Djaballah, H., & Shuman, S. (2007). Identification of novel antipoxviral agents: mitoxantrone inhibits vaccinia virus replication by blocking virion assembly. Journal of virology, 81(24), 13392-13402.",VACV
G2R,isatin-?-thiosemicarbazone (IBT),OPG087,Late transcription elongation factor,68857,69519,-,-,"Cresawn, S. G., Prins, C., Latner, D. R., & Condit, R. C. (2007). Mapping and phenotypic analysis of spontaneous isatin-thiosemicarbazone resistant mutants of vaccinia virus. Virology, 363(2), 319-332.",VACV
J6R,isatin-?-thiosemicarbazone (IBT),OPG105,DNA-dependent RNA polymerase subunit rpo147,81126,84986,-,-,"Cresawn, S. G., Prins, C., Latner, D. R., & Condit, R. C. (2007). Mapping and phenotypic analysis of spontaneous isatin-thiosemicarbazone resistant mutants of vaccinia virus. Virology, 363(2), 319-332.",VACV
A24R,isatin-?-thiosemicarbazone (IBT),OPG151,DNA-dependent RNA polymerase subunit rpo132,128924,132418,-,-,"Condit, R. C., Easterly, R., Pacha, R. F., Fathi, Z., & Meis, R. J. (1991). A vaccinia virus isatin-thiosemicarbazone resistance mutation maps in the viral gene encoding the 132-kDa subunit of RNA polymerase. Virology, 185(2), 857-861. Cresawn, S. G., Prins, C., Latner, D. R., & Condit, R. C. (2007). Mapping and phenotypic analysis of spontaneous isatin-thiosemicarbazone resistant mutants of vaccinia virus. Virology, 363(2), 319-332.",VACV
D13L,Rifampicin,OPG125,Rifampicin resistance protein,105999,107654,-,-,"Charity, J. C., Katz, E., & Moss, B. (2007). Amino acid substitutions at multiple sites within the vaccinia virus D13 scaffold protein confer resistance to rifampicin. Virology, 359(1), 227-232.",VACV
B5R,VIG,OPG190,EEV type-I membrane glycoprotein,165122,166075,-,-,"Bell, E., Shamim, M., Whitbeck, J. C., Sfyroera, G., Lambris, J. D., & Isaacs, S. N. (2004). Antibodies against the extracellular enveloped virus B5R protein are mainly responsible for the EEV neutralizing capacity of vaccinia immune globulin. Virology, 325(2), 425-431.",VACV
H1L,Aurintricarboxylic acid,OPG106,Tyr/ser protein phosphatase,84983,85498,-,-,"Myskiw, C., Deschambault, Y., Jefferies, K., He, R., & Cao, J. (2007). Aurintricarboxylic acid inhibits the early stage of vaccinia virus replication by Targeting both cellular and viral factors. Journal of virology, 81(6), 3027-3032.",VACV
H6R,"Ofloxacin, (other small molecules)",OPG111,DNA topoisomerase type I,90265,91209,-,-,"Bond, A., Reichert, Z., & Stivers, J. T. (2006). Novel and specific inhibitors of a poxvirus type I topoisomerase. Molecular pharmacology, 69(2), 547-557. Kamau, E., & Grove, A. (2004). Fluoroquinolone-dependent DNA supercoiling by vaccinia topoisomerase I. Journal of molecular biology, 342(2), 479-487.",VACV
I7L,TTP-6171,OPG083,Viral core cysteine proteinase,63445,64716,-,-,"Byrd, C. M., Bolken, T. C., Mjalli, A. M., Arimilli, M. N., Andrews, R. C., Rothlein, R., ... & Hruby, D. E. (2004). New class of orthopoxvirus antiviral drugs that block viral maturation. Journal of virology, 78(22), 12147-12156.",VACV
B1R,siRNA,OPG187,Ser/thr kinase,160622,161533,-,-,"Vigne, S., Duraffour, S., Andrei, G., Snoeck, R., Garin, D., & Crance, J. M. (2009). Inhibition of vaccinia virus replication by two small interfering RNAs targeting B1R and G7L genes and their synergistic combination with cidofovir. Antimicrobial agents and chemotherapy, 53(6), 2579-2588.",VACV
D5R,siRNA,OPG117,NTPase (1),96049,98406,-,-,"Vigne, S., Germi, R., Duraffour, S., Larrat, S., Andrei, G., Snoeck, R., ... & Crance, J. M. (2008). Specific inhibition of orthopoxvirus replication by a small interfering RNA targeting the D5R gene. Antiviral therapy, 13(3), 357-368.",VACV
J2R,(N) MCT 4?-thioIDU   5-substituted deoxyuridine analogs,OPG101,Thymidine kinase,78486,79019,-,-,"Kern, E. R., Prichard, M. N., Quenelle, D. C., Keith, K. A., Tiwari, K. N., Maddry, J. A., & Secrist III, J. A. (2009). Activities of certain 5-substituted 4-thiopyrimidine nucleosides against orthopoxvirus infections. Antimicrobial agents and chemotherapy, 53(2), 572-579. Prichard, M. N., Keith, K. A., Johnson, M. P., Harden, E. A., McBrayer, A., Luo, M., ... & Kern, E. R. (2007). Selective phosphorylation of antiviral drugs by vaccinia virus thymidine kinase. Antimicrobial agents and chemotherapy ,51(5), 1795-1803.",VACV
